Menu

Biocartis’ Idylla™ Instrument and Idylla™ Console exempt from US FDA 510(k) notification requirements

Non-regulated information

Biocartis and A*STAR’s ETPL initiate development of breast cancer assay to guide therapy selection

Non-regulated information

Biocartis launches CE-marked IVD test for lung cancer

Idylla™ EGFR Mutation Test is the only on market fully automated CE-IVD test detecting all relevant EGFR mutations according to international guidelines
Non-regulated information

MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform
Non-regulated information

Biocartis launches CE-marked IVD NRAS test for colorectal cancer

Non-regulated information

Study demonstrating high performance of Idylla™ liquid biopsy RAS tests to be presented at ASCO Annual Meeting

Non-regulated information

Biocartis establishes US subsidiary and appoints US General Manager

Non-regulated information

Biocartis receives grant for development of a fully automated MSI test

Test could be validated as prognostic test for colorectal cancer and predictive test for cancer immunotherapies
Non-regulated information

Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients

Study and editorial ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’ published in renowned clinical journal The Lancet Oncology
Non-regulated information

Important milestone in Biocartis-Merck collaboration with launch of second liquid biopsy assay

Non-regulated information